<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715039</url>
  </required_header>
  <id_info>
    <org_study_id>A9001141</org_study_id>
    <nct_id>NCT00715039</nct_id>
  </id_info>
  <brief_title>Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder</brief_title>
  <official_title>A 4-Week, Double-Blind, Randomized, Multicenter, Fixed Dose, Placebo-Controlled, Parallel Group Study of Lorazepam and Paroxetine in Patients With Generalized Anxiety Disorder: Assessment of a New Instrument Intended to Capture Rapid Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess the performance characteristics of a new measure to assess onset of
      efficacy in a GAD patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change from baseline over the first 6 days of treatment assessment (Study Days 2 through 7) on the Daily Assessment of Symptoms - Anxiety (DAS-A) questionnaire.</measure>
    <time_frame>baseline, days 2 through 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGIC at endpoint (LOCF)</measure>
    <time_frame>endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGIC at endpoint (LOCF)</measure>
    <time_frame>endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Q-LES-Q change from baseline to endpoint (LOCF)</measure>
    <time_frame>baseline, endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2 Mental Health change from baseline to endpoint (LOCF)</measure>
    <time_frame>baseline, endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS-A change from baseline to endpoint (LOCF)</measure>
    <time_frame>baseline, endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS-D change from baseline to endpoint (LOCF)</measure>
    <time_frame>baseline, endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to endpoint (Weeks 1, 2, 4, and 5) in the HAM-A total score.</measure>
    <time_frame>baseline and weeks 1,2,4, and 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to daily time point (Study Days 2 through 7) on the DAS-A.</measure>
    <time_frame>baseline and days 2 through 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS-A change from baseline to endpoint (LOCF)</measure>
    <time_frame>baseline to endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS-A 30% and 50% improvement at endpoint;</measure>
    <time_frame>endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS-A 30% sustained improvement beginning at week 1</measure>
    <time_frame>baseline, week1, 2,4,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A 30% sustained improvement beginning at week 1</measure>
    <time_frame>baseline, weeks 1,2,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAM-A 30% and 50% improvement at endpoint</measure>
    <time_frame>endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GA-VAS average change from baseline over the first 6 days</measure>
    <time_frame>baseline, days 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to daily time point on the GA-VAS(study days 2 through 7)</measure>
    <time_frame>baseline, days 2-7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GA-VAS change from baseline to endpoint</measure>
    <time_frame>aseline, endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GA-VAS sustained 30% improvement beginning at week 1</measure>
    <time_frame>baseline, weeks 1,2,4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GA-VAS 30% and 50% improvement at endpoint</measure>
    <time_frame>endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>lorazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>paroxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
    <description>1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days</description>
    <arm_group_label>lorazepam</arm_group_label>
    <other_name>Ativan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paroxetine</intervention_name>
    <description>20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind</description>
    <arm_group_label>paroxetine</arm_group_label>
    <other_name>Paxil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary Diagnosis of GAD (DSM IV, 300.02) as established by the clinician using all
             sources of data including the MINI structured interview

          -  HAM A score ³20 at the Screening (Study Day -7) and Baseline (Study Day 1) Visits by
             observer rating

          -  Good health as determined by medical history, physical examination, vital signs,
             electrocardiography (ECG), and clinical laboratory measurements

          -  Covi Anxiety Scale total score ³9 and Raskin Depression Scale total score £7 at the
             Screening Visit (to ensure predominance of anxiety symptoms over depression symptoms)

          -  Age 18 to 65 (inclusive)

        Exclusion Criteria:

          -  Patients with most other current DSM-IV Axis I disorders.

          -  Patients with current or past schizophrenia, Psychotic disorder

          -  Delirium, dementia, amnestic, and other clinically significant cognitive disorders

          -  Bipolar or schizoaffective disorder

          -  Benzodiazepine abuse or dependence; and/or Factitious disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Van Nuys</city>
        <state>California</state>
        <zip>91406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Casselberry</city>
        <state>Florida</state>
        <zip>32707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9001141&amp;StudyName=Clinical%20study%20assessing%20a%20new%20scale%20to%20measure%20onset%20of%20action%20in%20Generalized%20Anxiety%20Disorder</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>October 1, 2008</last_update_submitted>
  <last_update_submitted_qc>October 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>generalized anxiety disorder</keyword>
  <keyword>onset of efficacy</keyword>
  <keyword>Daily Assessment of Symptoms-Anxiety (DAS-A)</keyword>
  <keyword>Methods</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

